Who is eligible for clinical trial NCT06831552?

Participants must meet protocol criteria for Neuroblastoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06831552 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-09

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma (NCT06831552)

🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Dana-Farber Cancer Institute

🩺 Plain-English Summary (8th-Grade Level)

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (3 items).

Location: Connecticut Children's Medical Center — Hartford, Connecticut

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (\<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.
Patient newly diagnosed with high-risk neuroblastoma
Patient has established care at study site and initiated cancer-directed therapy
Patient has not yet initiated Induction Cycle 3
Patient aged 0-17 years at the time of consent
Parent/guardian screened positive for self-reported low-income (\<200% Federal Poverty) \*
Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
Patients of all languages are eligible to participate

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Foreign national family receiving care as an Embassy-pay patient.
Child or household member receiving SSI

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (6 Sites)

Connecticut Children's Medical Center — Hartford, Connecticut
Children's Healthcare of Atlanta — Atlanta, Georgia
Dana-Farber Cancer Institute — Boston, Massachusetts
Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center — Dallas, Texas
Seattle Children's Hospital — Seattle, Washington

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗